BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $134,000 | -60.8% | 10,677 | -49.2% | 0.02% | -40.5% |
| Q1 2022 | $342,000 | -82.1% | 21,035 | -91.8% | 0.04% | -76.1% |
| Q4 2020 | $1,908,000 | +418.5% | 256,210 | +231.4% | 0.16% | +307.9% |
| Q2 2020 | $368,000 | +332.9% | 77,301 | +212.9% | 0.04% | +1166.7% |
| Q4 2019 | $85,000 | +3.7% | 24,704 | -14.7% | 0.00% | -25.0% |
| Q3 2019 | $82,000 | -57.3% | 28,949 | +21.6% | 0.00% | -60.0% |
| Q4 2018 | $192,000 | -55.1% | 23,800 | -68.2% | 0.01% | +11.1% |
| Q2 2018 | $428,000 | +46.1% | 74,800 | -27.9% | 0.01% | -35.7% |
| Q1 2016 | $293,000 | +35.0% | 103,800 | +443.5% | 0.01% | -12.5% |
| Q3 2015 | $217,000 | -15.9% | 19,100 | +10.4% | 0.02% | -59.0% |
| Q2 2015 | $258,000 | +113.2% | 17,300 | +50.4% | 0.04% | +550.0% |
| Q1 2014 | $121,000 | – | 11,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |